NEWPORT BEACH, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:PMGC) (the "Company," "PMGC," "we," or "us"), a diversified public holding company, is pleased to announce the signing of a non-binding Letter of Intent ("LOI") to acquire a U.S.-based, cash-flow positive information technology ("IT") custom packaging company. About the Target Company Founded in 2011 and headquartered in Southern California, the Target is a well-established provider of custom packaging solutions for IT prod ...

Northstrive Biosciences and Yuva Biosciences’ collaboration will leverage MitoNova™, YuvaBio’s proprietary mitochondrial science-focused artificial intelligence platform, to discover and develop novel pharmaceutical treatments for obesity, type 2 diabetes and other cardiometabolic conditions.Northstrive and Yuva Biosciences will compile a library of small molecule candidates that promote mitochondrial health and target the root cause of aging at the cellular level. NEWPORT BEACH, Calif., April 10, 2025 (GL ...

Core Viewpoint - PMGC Holdings Inc. has filed its Annual Report for the fiscal year ended December 31, 2024, with the SEC, highlighting its commitment to innovative solutions and long-term shareholder value [1][2]. Company Overview - PMGC is a diversified holding company that manages a portfolio through strategic acquisitions, investments, and development across various industries [3]. - The current portfolio includes three wholly owned subsidiaries: Northstrive Biosciences Inc., PMGC Research Inc., and PMGC Capital LLC [3]. Strategic Initiatives - The company is actively seeking acquisition opportunities that can drive meaningful revenue growth and enhance shareholder value as part of its strategic growth initiatives [2].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-41875 PMGC HOLDINGS INC. (Exact name of registrant as specified in its charter) Nevada 33-2382547 (State or other jurisdiction of incorporation or organization) FORM 10-K ☒ ANNUAL REPORT PURUANT TO SECTION 13 OR 15(d) OF ...

Company Overview - PMGC Holdings Inc. announced a significant amendment to its License Agreement with MOA Life Plus Co., Ltd. for its subsidiary NorthStrive Biosciences, expanding the license rights to all uses in animal health, including feed additives [1][2] - NorthStrive Biosciences aims to capture new revenue streams from high-growth markets and lower barriers to entry in the animal health pharmaceutical sector [2][3] - The company focuses on developing advanced solutions to meet unmet needs in the U.S. animal health market [2][3] Industry Insights - The U.S. animal health market was valued at USD 12.65 billion in 2024 and is projected to grow at a CAGR of 7.97% from 2025 to 2030 [7] - Growth factors include innovations in companion animal pharmaceuticals, increasing pet adoption rates among millennials, and rising livestock populations in developing countries [7] - The amendment allows NorthStrive Biosciences to develop a comprehensive range of animal health products, which are essential for improving animal health and food security [7]

Group 1 - Univest Securities, LLC announced the closing of a registered direct offering for PMGC Holdings Inc., raising approximately $1.48 million through the sale of 294,450 shares at a price of $5.04 per share [1][2][3] - The offering was conducted under a shelf registration statement previously filed and declared effective by the SEC on February 7, 2025 [4] - PMGC Holdings Inc. is a diversified holding company with a portfolio that includes three wholly owned subsidiaries: Northstrive Biosciences Inc., PMGC Research Inc., and PMGC Capital LLC [7]

Core Viewpoint - PMGC Holdings Inc. has entered into a definitive agreement for a registered direct offering of 294,450 shares at a price of $5.04 per share, expected to raise approximately $1.48 million in gross proceeds [1][2]. Group 1: Offering Details - The offering involves the sale of common stock or pre-funded warrants, with the purchase price for the pre-funded warrants being the same as the shares, minus an exercise price of $0.001 per share [1]. - The transaction is anticipated to close on or about March 24, 2025, pending customary closing conditions [2]. - The company will have approximately 872,411 shares of common stock issued and outstanding following the offering [1]. Group 2: Regulatory Information - The offering is conducted under a shelf registration statement on Form S-3, which was declared effective by the SEC on February 7, 2025 [3]. - A final prospectus supplement and accompanying prospectus will be filed with the SEC, detailing the terms of the offering [3]. Group 3: Company Overview - PMGC Holdings Inc. is a diversified holding company that manages a portfolio through strategic acquisitions and investments across various industries [5]. - The company's portfolio includes three wholly owned subsidiaries: Northstrive Biosciences Inc., PMGC Research Inc., and PMGC Capital LLC [5].

Group 1 - PMGC Holdings Inc. has repurchased shares from certain existing shareholders who contacted the company directly, with details available in the Company's Form 8-K filings [1] - The company is open to considering additional share repurchases from other investors, depending on market conditions and other factors [1] - Shareholders interested in discussing potential repurchases are encouraged to contact the company directly in writing [2] Group 2 - PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries [4] - The company's portfolio currently consists of three wholly owned subsidiaries: Northstrive Biosciences Inc., PMGC Research Inc., and PMGC Capital LLC [4] - The company is committed to exploring opportunities in multiple sectors to maximize growth and value [4]

Core Insights - Northstrive Biosciences Inc. has scheduled a pre-Investigational New Drug (pre-IND) meeting with the FDA on April 23, 2025, to discuss the path forward for filing an IND for EL-22 as a combination treatment with GLP-1 for muscle preservation [1][3][7] - EL-22 is a novel engineered probiotic designed to express myostatin on its surface, targeting the myostatin pathway to support muscle health, with preclinical studies showing significant improvements in models of Duchenne muscular dystrophy [2][4] - The company aims to file the IND application in 2025 and initiate clinical trials to evaluate the combination of EL-22 with GLP-1 receptor agonists for obesity treatment [3][4] Company Overview - Northstrive Biosciences Inc. is a subsidiary of PMGC Holdings Inc., focusing on the development of innovative aesthetic medicines, with EL-22 being its lead asset [4][5] - PMGC Holdings Inc. is a diversified holding company managing a portfolio through strategic acquisitions and investments across various industries [5]

Core Viewpoint - PMGC Holdings Inc. will implement a 1-for-7 reverse stock split effective March 10, 2025, to comply with Nasdaq listing requirements and enhance its market presence [1][3][4] Purpose of the Reverse Stock Split - The reverse stock split is essential for maintaining compliance with Nasdaq's listing requirements, which will enhance visibility and investor confidence, positioning the company for future growth [3] - There is no guarantee that the company will meet the minimum bid price requirement after the split [3] Nasdaq Rule Changes and Compliance Considerations - The reverse stock split is in response to recent Nasdaq rule changes aimed at ensuring compliance with listing requirements, particularly maintaining a stable share price above the minimum threshold [4] - The amendments highlight the company's commitment to addressing potential noncompliance issues proactively [4] Impact on Shareholders - Every 7 shares of common stock will consolidate into one share automatically, with no action required from shareholders [7] - Fractional shares will be rounded up to one full share for each fractional portion [7] - The trading symbol will remain "ELAB," but a new CUSIP number will be assigned [7] - Adjustments will be made to outstanding stock awards, options, and warrants to reflect the reverse split [7] Post-Split Share Structure - Post-split, approximately 577,000 shares of common stock will be issued and outstanding as of March 10, 2025 [9] - The total number of authorized shares will also decrease at the same 1-for-7 ratio as the issued and outstanding shares [9]